INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders.
SUBATM-Itraconazole, the company’s lead product candidate, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, which, when studied to tre...
INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders.
SUBATM-Itraconazole, the company’s lead product candidate, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, which, when studied to treat patients with cancer, has demonstrated activity against multiple tumor types. INHIBITOR is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC)
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.